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Blood-based biomarkers for Alzheimer’s disease and related dementias:
Keys to success and things to considerDuring the last two decades, considerable progress has
been made in the field of fluid and imaging biomarkers for
neurodegenerative dementias. As a result, the most recent
research and clinical guidelines (the National Institute on
Aging and Alzheimer’s Association, International Working
Group 2, National Institute for Health and Care Excellence)
incorporate cerebrospinal fluid (CSF) and positron emission
tomography (PET) biomarkers in the diagnostic criteria of
dementia and mild cognitive impairment due to Alzheimer’s
disease (AD) [1–3]. However, as both CSF and amyloid PET
examinations require expert knowledge and are of limited
availability outside specialized memory clinics, there is no
doubt that blood tests would be much easier to implement
in clinical medicine and as screening tools when recruiting
patients for clinical trials.
However, there are several issues, both biological and
technical, with the measurement of biomarkers for neurode-
generative dementias in blood. First, a biomarker that has its
origin in the central nervous system (CNS) has to cross the
blood-brain barrier to be detected in the periphery, and if
the concentration in CSF is low, it will be even lower in
the blood. Second, if the biomarker is not specific for the
CNS but also expressed in peripheral tissues, the contribu-
tion from the CNS will potentially be hard to detect, given
the high biological background caused by non-CNS sources.
Third, the broad dynamic range of the plasma proteome,
which is dominated by plasma proteins, such as albumin
and immunoglobulins, with only minute amounts of CNS-
derived proteins, presents an analytical challenge [4].
Fourth, heterophilic antibodies may be present in blood,
which may interfere in immunoassays [5]. Fifth, the analyte
of interest may undergo proteolytic degradation by various
proteases in plasma [6]. Sixth, clearance of the biomarker
by the liver or the kidneys, diurnal variation, and plasma vol-
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able progress in the field. Ultrasensitive high-precision as-
says that allow for the accurate determination of a ratio of
42 to 40 amino acid-long amyloid b (Ab42/Ab40) can
now detect cerebral b-amyloidosis (determined by amyloid
PET) with 70–90% diagnostic accuracy [7–11], which is
almost as good as the corresponding CSF test [12]. Serum
or plasma neurofilament light (NfL) is emerging as a reliable
biomarker for neurodegeneration and neuronal injury, irre-
spective of underlying cause [13]. Promising results also
exist for plasma p-tau, measured using a sensitive immuno-
assay with electrochemiluminescence detection [14].
Several large replication studies, showing robust correla-
tions of plasma p-tau concentration with CSF p-tau and am-
yloid PET results, were presented during the Alzheimer’s
Association International Conference 2019 with publica-
tions in preparation. Promising results have also been
published in regards to multimarker plasma proteomic pro-
files that may be used to detect cerebral b-amyloidosis in
AD [15].
How come this field has developed in such an unexpect-
edly good way? The most important explanation is probably
improved analytical sensitivity and specificity of the
biomarker assays. Recent technological breakthroughs
now allow for biomarker measurements in the subfemtomo-
lar concentration range. This means that small amounts of
CNS-derived proteins can be isolated and quantified from
the complex blood matrix in a reliable manner. The matrix
can also be diluted to remove some of the interfering factors
described previously. Much more attention has also been
paid to preanalytical sample handling, and consensus proto-
cols regarding this have been published [16,17]. Finally, it is
essential to remember that modern biomarker research is
now performed on much more well-characterized cohorts
than only 5–10 years ago. The reference standard used to
classify study participants nowadays often includes, in addi-
tion to careful clinical examination, advanced neuroimaging
and molecular markers of AD pathology. Researchers are
increasingly making sure that their control group is amyloid
free, whereas the AD group is amyloid positive using amy-
loid PET or the CSF Ab42/Ab40 ratio. In addition, from a
basic technical point of view, many of the blood tests nowimer’s Association. This is an open access article under the CC BY-NC-ND
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research and a clinical standpoint, the variation of many
candidate blood biomarkers for neurodegenerative demen-
tias is also carefully examined now, taking into account kid-
ney and liver function, body constitution, and diurnal
variation.
This special issue of Alzheimer’s & Dementia: Diag-
nosis, Assessment & Disease Monitoring is a follow-up
on the article series on blood biomarkers for AD pub-
lished 3 years ago [18]. The rationale to develop another
special issue on this particular topic stems from the enor-
mous research intensity in the field. In this special issue,
we present the reader with articles on single and multi-
plexed biomarkers targeting different neurodegenerative
pathologies, including traumatic brain injury and demen-
tia with Lewy bodies. Although the majority of the man-
uscripts in this issue are reflecting on tau- and Ab-related
processes, we also include novel compelling findings
focused on complement proteins and work reflecting fields
of lipidomics and metabolomics.
We have every reason to believe that the blood-based
biomarker toolbox will undergo further expansion during
the coming years and move toward clinical implementation.
There is a lot more work to be performed, however, particu-
larly regarding biomarkers for non-AD neurodegenerative
diseases. We anticipate seeing such markers emerging dur-
ing the coming years, and hopefully, these will facilitate
drug development and allow for efficient drug selection
and dose finding, once we have disease-modifying drugs to
prescribe.
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